|
Age (in years)
|
50.2
|
23.8-75.9
|
50.6
|
22.5-78.0
|
50.6
|
22.5-78.0
|
|
Number of nodes removed
|
19
|
5-59
|
19
|
4-53
|
19
|
4-59
|
|
Number of positive nodes
|
7
|
0-54
|
6
|
0-49
|
6
|
0-54
|
| |
N
|
%
|
N
|
%
|
N
|
%
|
|
Nodal involvement (n = 352)
| | | | | | |
|
0-3 nodes
|
34
|
21.4
|
54
|
28.0
|
88
|
25.0
|
|
≥ 4 nodes
|
125
|
78.6
|
139
|
72.0
|
264
|
75.0
|
|
Menopausal status (n = 352)
| | | | | | |
|
Premenopausal
|
83
|
52.2
|
104
|
53.9
|
187
|
53.1
|
|
Postmenopausal
|
76
|
47.8
|
89
|
46.1
|
165
|
46.9
|
|
Type of operation (n = 352)
| | | | | | |
|
Modified radical mastectomy
|
122
|
76.7
|
151
|
78.2
|
273
|
77.6
|
|
Breast conserving surgery
|
37
|
23.3
|
42
|
21.8
|
79
|
22.4
|
|
Interval from operation (n = 352)
| | | | | | |
|
< 2 weeks
|
19
|
11.9
|
26
|
13.5
|
45
|
12.8
|
|
2-4 weeks
|
81
|
50.9
|
84
|
43.5
|
165
|
46.9
|
|
> 4 weeks
|
59
|
37.1
|
83
|
43.0
|
142
|
40.3
|
|
Tumor grade* (n = 351)
| | | | | | |
|
I-II
|
64
|
40.5
|
112
|
58.0
|
176
|
50.1
|
|
III-Undifferentiated
|
94
|
59.5
|
81
|
42.0
|
175
|
49.9
|
|
Tumor size (n = 352)
| | | | | | |
|
< 2 cm
|
45
|
28.3
|
67
|
34.7
|
112
|
31.8
|
|
2-5 cm
|
88
|
55.3
|
91
|
47.2
|
179
|
50.9
|
|
> 5 cm
|
26
|
16.4
|
35
|
18.1
|
61
|
17.3
|
|
Adjuvant RT (n = 350)
| | | | | | |
|
No
|
27
|
17.1
|
39
|
20.3
|
66
|
18.9
|
|
Yes
|
131
|
82.9
|
153
|
79.7
|
284
|
81.1
|
|
Adjuvant HT (n = 351)
| | | | | | |
|
No
|
12
|
7.6
|
21
|
10.9
|
33
|
9.4
|
|
Yes
|
146
|
92.4
|
172
|
89.1
|
318
|
90.6
|
|
ER protein status (n = 306)
| | | | | | |
|
Negative
|
40
|
28.2
|
41
|
25.0
|
81
|
26.5
|
|
Positive
|
102
|
71.8
|
123
|
75.0
|
225
|
73.5
|
|
PgR protein status (n = 305)
| | | | | | |
|
Negative
|
52
|
36.6
|
54
|
33.1
|
106
|
34.8
|
|
Positive
|
90
|
63.4
|
109
|
66.9
|
199
|
65.2
|
|
Hormone receptor status (n = 307)
| | | | | | |
|
Negative
|
36
|
25.4
|
29
|
17.6
|
65
|
21.2
|
|
Positive
|
106
|
74.6
|
136
|
82.4
|
242
|
78.8
|
|
Ki67 (n = 309)
| | | | | | |
|
Low (< 14%)
|
25
|
17.4
|
30
|
18.2
|
55
|
17.8
|
|
High (≥ 14%)
|
119
|
82.6
|
135
|
81.8
|
254
|
82.2
|
|
HER2 CISH amplification (n = 285)
| | | | | | |
|
Non-amplified
|
100
|
75.2
|
121
|
79.6
|
221
|
77.5
|
|
Amplified
|
33
|
24.8
|
31
|
20.4
|
64
|
22.5
|
|
HER2 mRNA expression (n = 314)
| | | | | | |
|
Low (< 75th percentile)
|
108
|
75.0
|
128
|
75.3
|
236
|
75.2
|
|
High (≥ 75th percentile)
|
36
|
25.0
|
42
|
24.7
|
78
|
24.8
|
|
HER2 protein expression (n = 297)**
| | | | | | |
|
0-1+
|
86
|
63.2
|
125
|
77.6
|
211
|
71.0
|
|
2+
|
19
|
14.0
|
15
|
9.3
|
34
|
11.4
|
|
3+
|
31
|
22.8
|
21
|
13.0
|
52
|
17.5
|
|
TOP2A CISH amplification (n = 266)
| | | | | | |
|
Non-amplified
|
110
|
90.9
|
137
|
94.5
|
247
|
92.9
|
|
Amplified
|
11
|
9.1
|
8
|
5.5
|
19
|
7.1
|
|
TOP2A mRNA expression (n = 314)
| | | | | | |
|
Low (< median)
|
72
|
50.0
|
85
|
50.0
|
157
|
50.0
|
|
High (≥ median)
|
72
|
50.0
|
85
|
50.0
|
157
|
50.0
|
|
TopoIIa protein status (n = 273)
| | | | | | |
|
Negative
|
43
|
35.2
|
56
|
37.1
|
99
|
36.3
|
|
Positive
|
79
|
64.8
|
95
|
62.9
|
174
|
63.7
|
